| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -185,000 | -128,556 | -180,413 | -266,031 |
| Stock-based compensation | 30,000 | 37,289 | 37,265 | 78,446 |
| Amortization of discount on marketable securities, net | 1,000 | 516 | 704 | 2,780 |
| Depreciation and amortization | 8,000 | 8,785 | 8,606 | 17,609 |
| Non-cash royalty revenue | 20,000 | 37,581 | 24,911 | 49,508 |
| Non-cash interest expense on liabilities for sales of future royalties | 21,000 | 19,469 | 14,148 | 28,383 |
| Other | -1,000 | -693 | 273 | 2,420 |
| Accounts receivable | -19,000 | 33,834 | -5,425 | 2,591 |
| Inventory | 4,000 | -150 | 5,595 | 555 |
| Prepaid expenses and other assets | 9,000 | 2,740 | -9,905 | 17,165 |
| Accounts payable, accrued, and other liabilities | -57,000 | 37,012 | 45,124 | -58,136 |
| Net cash used in operating activities | -197,000 | -99,829 | -91,423 | -274,748 |
| Purchase of property, plant, and equipment | 1,000 | 938 | 1,278 | 3,784 |
| Purchase of marketable securities | 131,000 | 153,555 | 16,942 | 15,503 |
| Proceeds from sale of marketable securities | NaN | -143 | 0 | 143 |
| Proceeds from maturities of marketable securities | 88,000 | 82,116 | 135,587 | 226,297 |
| Payments for intangible asset | 5,000 | 0 | 0 | 15,000 |
| Other | 0 | -273 | 185 | 1,088 |
| Net cash (used in) provided by investing activities | -49,000 | -72,247 | 117,182 | 191,065 |
| Proceeds from the sale of future royalties, net | NaN | 392,000 | NaN | NaN |
| Proceeds from the issuance of common stock and pre-funded warrants in connection with underwritten public offerings, net | NaN | 0 | 0 | 0 |
| Proceeds from the issuance of common stock in connection with at-the-market offering, net | NaN | 272 | 0 | 79,728 |
| Proceeds from the issuance of common stock under equity plan awards, net of tax | NaN | NaN | -2 | -4,078 |
| Proceeds from the issuance of common stock under equity plans, net | NaN | 6,000 | NaN | NaN |
| Proceeds from issuance of equity from noncontrolling interest | NaN | 0 | 0 | NaN |
| Other | NaN | 0 | NaN | NaN |
| Net cash provided by financing activities | NaN | 394,192 | 2 | 83,806 |
| Effect of exchange rate changes on cash | -1,000 | -656 | 294 | 4,362 |
| Net decrease in cash, cash equivalents and restricted cash | -247,000 | 221,460 | 26,055 | 4,485 |
| Cash, cash equivalents and restricted cash at beginning of period | 436,000 | 214,699 | 184,159 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 189,000 | 436,000 | 214,699 | NaN |
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)